〜Unleashing SLC Transporters Against Incurable Disease〜
In an era where wellness and equity are paramount, SIIF Impact Capital, Inc. took a holistic approach to this impactful investment. Leveraging systems thinking tools, including causal loop diagrams and logic models, SIIF Impact Capital engaged in deep dialogues with cancer patients, families, healthcare professionals, pharmaceutical experts, and regulators. The outcome was crystal clear: J-Pharma Co., Ltd’s visionary founder, Dr. Hitoshi Endo, shares our passion for creating a healthcare system that nurtures hope, even among those bravely battling advanced cancer.
“Our commitment goes beyond the conventional metrics of cancer treatment; we’re dedicated to enhancing patients’ quality of life and fostering holistic wellness. This impact investment in J-Pharma Co., Ltd is a catalyst for system change in the cancer treatment landscape,”
〜Kazu Umeda, Representative Partner of SIIF Impact Capital, Inc.〜
J-Pharma Co., Ltd stands as the world’s sole startup conducting clinical trials of LAT1 inhibitors, an exciting frontier in cancer research. Dr. Hitoshi Endo, in collaboration with Professor Yoshikatsu Kanai of Osaka University Graduate School of Medicine, isolated LAT1 in 1998, a cell membrane transporter that plays a pivotal role in amino acid uptake. LAT1’s high expression in cancer cells renders it an enticing target for cancer therapy.
The spotlight shines brightest on JPH203, the most advanced drug candidate in development. This groundbreaking compound offers hope to those battling biliary tract cancer afflicting the bile ducts and causing 23,000 annual cases and 18,000 deaths in Japan alone. Currently ranked seventh in incidence and second-lowest in five-year survival rates among 21 types of cancer (source: National Cancer Center Cancer Information Service), biliary tract cancer’s relentless grip may finally yield to JPH203’s cancer-specific, gentle mechanism of action. The dream of a healthcare system that continues to inspire hope is no longer distant.
J-Pharma Co., Ltd’s innovation extends beyond JPH203, boasting a robust pipeline of drug candidates targeting various cancers and rare genetic disorders. Among them, JPH034 emerges as a potential game-changer for multiple sclerosis.
SIIF Impact Capital, Inc. is a venture capital stalwart, unwavering in its commitment to investments that yield both social and environmental benefits alongside financial returns. This impact investment in J-Pharma Co., Ltd underscores SIIF Impact Capital, Inc.’s enduring mission to empower companies creating positive societal impacts. This investment will advance J-Pharma Co., Ltd’s drug discovery initiatives and its portfolio of groundbreaking drug candidates.
“With the support of investors like SIIF Impact Capital, Inc., we’ve raised an additional 2.4 billion yen in Series E. Progress in our JPH203 and JPH034 projects has been substantial. We are committed to meeting the expectations of our shareholders, patients seeking effective treatments, and healthcare professionals.”
〜Masuhiro Yoshitake, President & CEO of J-Pharma Co., Ltd〜
J-Pharma Co., Ltd’s mission is nothing short of awe-inspiring: to develop innovative drugs that enhance patient outcomes. Their LAT1 inhibitor drug candidates hold the potential to transform cancer treatment by minimizing side effects. Through their clinical trials of JPH203 for biliary tract cancer, a disease with limited therapeutic options, J-Pharma Co., Ltd aims to usher in a healthcare era where even advanced cancer patients can embrace hope.
For further insights into J-Pharma Co., Ltd’s groundbreaking drug discovery efforts, visit their website at https://www.j-pharma.com/en/.
For media inquiries and additional information, please contact:
About SIIF Impact Capital, Inc.:
SIIF Impact Capital, Inc. is a trailblazing venture capital firm dedicated to investing in companies that generate positive social and environmental impacts alongside robust financial returns. With a steadfast commitment to wellness and equity, SIIF Impact Capital, Inc. continues to empower enterprises that make a meaningful difference in society. For more information, please visit https://www.siific.co.jp/.
About J-Pharma Co., Ltd:
J-Pharma Co., Ltd is a pioneering biotech firm leading the charge in innovative drug discovery. Armed with a deep understanding of disease biology and cutting-edge technologies, they’re on a mission to develop transformative treatments for cancer and rare genetic disorders. Their groundbreaking LAT1 inhibitor drug candidates offer hope for a brighter, healthier future. To learn more, please visit https://www.j-pharma.com/en/.
Note: This press release is for informational purposes only and does not constitute an offer or solicitation for investment.